Pitfalls in surveillance for hepatocellular carcinoma: How successful is it in the real world?
Linda L. Wong, Ruel J. Reyes, Sandi A. Kwee, Brenda Y. Hernandez, Sumodh C. Kalathil, Naoky C. Tsai
Clin Mol Hepatol. 2017;23(3):239-248.   Published online 2017 Jul 14     DOI: https://doi.org/10.3350/cmh.2017.0008
Citations to this article as recorded by Crossref logo
Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration
Y. A. Patel, E. J. Gifford, L. M. Glass, R. McNeil, M. J. Turner, B. Han, D. Provenzale, S. S. Choi, C. A. Moylan, C. M. Hunt
Alimentary Pharmacology & Therapeutics.2018; 47(2): 268.     CrossRef
Diffusion-weighted MRI as a screening tool for hepatocellular carcinoma in cirrhotic livers: correlation with explant data—a pilot study
M. M. McNamara, J. V. Thomas, L. F. Alexander, M. D. Little, D. N. Bolus, Yufeng E. Li, D. E. Morgan
Abdominal Radiology.2018;[Epub]     CrossRef
Treatment for occult hepatocellular carcinoma: does it offer survival advantages over symptom-driven treatment?
Kwang Min Kim, Jiyu Kim, Dong Hyun Sinn, Hye Seung Kim, Kyunga Kim, Wonseok Kang, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Kwang Cheol Koh, Seung Woon Paik
Scandinavian Journal of Gastroenterology.2018; : 1.     CrossRef
Surveillance of hepatocellular carcinoma: is only ultrasound enough?
Woo Kyoung Jeong
Clinical and Molecular Hepatology.2017; 23(3): 222.     CrossRef